Cooley advised Neogene Therapeutics, a global clinical-stage biotechnology company, on its definitive agreement to be acquired by AstraZeneca for a total consideration of up to $320 million, on a cash and debt-free basis, including an upfront payment of $200 million and up to $120 million payable upon achievement of certain milestones.
Key deals, decisions + trends
Close